Skip to content
Search

Latest Stories

Prefer paracetamol to ibuprofen to treat COVID-19 symptoms, NHS advises

There currently is no evidence which links anti-inflammatory medicines such as ibuprofen with the worsening of COVID-19, NHS said on Wednesday.

The agency, however, advised to take paracetamol to treat symptoms of COVID-19, until more information is available, adding that regulatory agencies are reviewing the evidence.


“In view of the current lack of clarity the Committee of Human Medicines (an advisory body of MHRA) and NICE have been asked to review the evidence,” said Stephen Powis, medical director at NHS England.

“It is therefore suggested that, in the interim, for patients, who have confirmed COVID-19 or believe they have COVID-19, that they use paracetamol in preference to NSAIDs (non-steroidal anti-inflammatory drugs).”

Powis added that patients already being treated with anti-inflammatory drugs for other medical reasons should not stop them.

The World Health Organization on Tuesday recommended that people suffering from COVID-19-like symptoms should avoid self-medicating with ibuprofen, after French authorities warned anti-inflammatory drugs could worsen the effects of the virus.

The warnings over the weekend by French Health Minister Olivier Veran, a clinician himself, followed a recent study in The Lancet weekly medical journal that hypothesised that an enzyme that is boosted when taking anti-inflammatory drugs like ibuprofen could facilitate and worsen COVID-19 infections.

Reckitt Benckiser (RB), the makers of Nurofen products, said it is aware of "the ongoing spread of information" concerning the use of NSAIDs including ibuprofen, but requested patients and healthcare professionals to consider each case separately.

The firm said all available treatment options, including paracetamol and NSAIDs, should be considered when starting treatment for fever or pain in COVID-19, noting that the European Medicines Agency (EMA), World Health Organisation as well as NHS has stated that there is currently no strong scientific evidence linking ibuprofen usage to worsening of COVID-19.

"Consumer safety is our number one priority. Ibuprofen is a well-established medicine that has been used with a good safety profile as a fever and pain reducer for more than 30 years," it said.

The EMA on Wednesday said that there currently is no evidence to link anti-inflammatory medicines such as ibuprofen with the worsening of COVID-19.

The EU regulator added that it was monitoring the situation, but took a similar tone to RB in suggesting patients and healthcare professionals to consider all treatment options including paracetamol and anti-inflammatory drugs to treat fever or pain in patients with COVID-19.

The COVID-19 pandemic causes mild symptoms in most people, but can result in pneumonia and in some cases severe illness that can lead to multiple organ failure.

More For You

Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
Aspire Pharma acquisition boosts access to essential medicines for NHS patients in the UK

The acquisition is expected to further drive the company’s growth.

gettyimages

Aspire acquires UK distribution rights from Tetris

Aspire Pharma Limited, one of the UK’s fastest-growing specialty niche generics companies, has announced the acquisition of UK distribution rights to a number of products from Tetris Pharma, a subsidiary of Arecor Therapeutics.

These include products used in the treatment of bacterial infections—such as injectable and intravenous antibiotics—as well as a medicine indicated for acute myocardial infarction (MI) and deep vein thrombosis (DVT).

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less